medigraphic.com
ISSN 1561-3011 (Electronic)

2014, Number 2

<< Back Next >>

Rev Cubana Invest Bioméd 2014; 33 (2)

Detection of the epidermal growth factor receptor by relaxometry of oral premalignant lesions

Alonso GY, De la Cruz ER, Dutok SCM, Álvarez GED

Language: Spanish
References: 22
Page: 150-156
PDF size: 174. Kb.


ABSTRACT

Objective: Detect the overexpression of the epidermal growth factor receptor in epithelial cells of premalignant lesions of the oral mucosa magnetically marked by relaxometry.
Methods: Exfoliated oral mucosa cells from healthy and sick individuals were marked with the system biotinylated anti-EGF-R IgG / anti-biotin IgG conjugated with supermagnetic particles and measurements were taken of relaxation times T1 and T2.
Results: In all the samples analyzed there was a decrease in the relaxation times (T1 and T2) of marked cells with respect to unmarked cells. Comparison of the T1 and T2 values of marked cells from the lesion with the values of healthy cells revealed a statistically significant decrease in relaxation time. Comparison of the relaxation times of healthy marked cells with those of cells from the various lesions revealed statistically significant differences in both T1 and T2 in cells from lichen planus and leukoplakias, but not in cells from keratoses.
Conclusions: Results show that relaxometry may be used to detect cells expressing the epidermal growth factor receptor, using the conjugated system described herein, and that EGF-R is overexpressed in cells from lesions such as leukoplakia and lichen planus.


REFERENCES

  1. Pavlova I, Williams MD, El-Naggar A, Richards-Kortum R, Gillenwater A. Understanding the biological basis of autofluorescence imaging for oral cancer detection: high resolution fluorescence microscopy in viable tissue. Clin Cancer Res 2008;14(8):2396-2404.

  2. Moore SR, Johnson NW, Pierce AM, Wilson DF. The epidemiology of mouth cancer: a review of global incidence. Oral Diseases 2000;6(29):65-74.

  3. Epstein JB, Gorsky M, Cabay RJ, Day T, Gonsalves W. Screening for and diagnosis of oral premalignant lesions and oropharyngeal squamous cell carcinoma: Role of primary care physicians. Can Fam Physician 2008;54(6):870-875.

  4. Schwarz RA, Gao W, Redden Weber C, Kurachi C, Lee JJ, El-Naggar AK et al. Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer 2009;115(8):1669-79.

  5. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med. 2008;37(1):1-10.

  6. González MA, Gil JA, Ruiz I. Bases moleculares de la cancerización de cavidad oral. Avances en odontoestomatología 2008;24(1):55-60.

  7. Sano D, Choi S, Milas ZL, Zhou G, Galer CE, Su YW, et al. The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis: A Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral Tongue. Arch Otolaryngol Head Neck Surg. 2009 Apr; 135(4):411-420.

  8. Scully C, Sudbo J, Speight PM. Progress in determining the malignant potential of oral lesions. J Oral Pathol Med. 2003 May; 32(5):251-256.

  9. Gillenwater A, Papadimitrakopoulou V, Richards-Kortum R. Oral premalignancy: new methods of detection and treatment. Curr Oncol Rep. 2006;8:146-154.

  10. Jesper R. Prognosis of oral pre-malignant lesions: significance for clinical, histopathological, and molecular biological characteristics. Critical Reviews in Oral Biology & Medicine 2003;14(1):47-62.

  11. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007;36(10):575-80.

  12. Chen AY, Myers JN. Cancer of the oral cavity. Dis Mon. 2001;47:275-361.

  13. Soukos NS, Hamblin MR, Keel S, et al. Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 2001;61:4490-4496.

  14. Pico MC, Giraldo IG, Otero A. Inmunología Experimental. La Habana (Cuba): Editorial Felix Varela; 1997.p.246-275.

  15. PIERCE Biotechnology Inc. Instructions EZ-Link® NHS-Biotin Reagents. PIERCE Biotechnology Inc 9/2004 [publicación en línea] 2004 [fecha de acceso: 22 Dic 2012]; 9. Disponible en: http://www.piercenet.com.

  16. Miltenyi Bistec Inc. Instructions MACS Magnetic Cell Sorting with indirect MicroBeads. Miltenyi Bistec Inc, USA [publicación en línea] 2007 [fecha de acceso: 22 Dic 2012]. Disponible en: http://www.miltenyibiotec.com.

  17. Lores M, Rodrigues Y, Pérez E. Evaluación de las potencialidades de la relajación magnética nuclear para el estudio, a baja frecuencia, del cáncer de mama in vitro. Revista Cubana de Química 2002;14(3):3-10.

  18. Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu L, et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 2001,7:4230-38.

  19. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4(1):121-33.

  20. Jorrissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Experimental Cell Research 2003;281(1):31-53.

  21. Tarakji B, Kujan O, Nassani MZ. An immunohistochemical study of the distribution of p 16 protein in oral mucosa in smokers, non-smokers and in frictional keratosis. Med Oral Patol Oral Cir Bucal 2010;15(5):681-4.

  22. Werkmeister R, Brandt B, Joos V. Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol 2000;36:100-5.




2020     |     www.medigraphic.com